Friday, November 13, 2026

Dollar Falls to 2022 Low as Euro Climbs 14%, Unwinding Global Carry Trades

The US Dollar dropped to its weakest level since 2022 as the Euro gained 14% and the British Pound rose 7% in 2025. The shift triggered widespread unwinding of carry trades in emerging markets, with currency volatility reaching levels unseen since the 2022 Fed tightening cycle ended.

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Dollar Falls to 2022 Low as Euro Climbs 14%, Unwinding Global Carry Trades
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US Dollar fell to its lowest level since 2022, declining across all major trade-weighted baskets as the Euro surged 14% and the British Pound gained 7% in 2025. The realignment marks one of the sharpest currency moves in recent years, spanning developed and emerging markets.

The Swiss Franc also strengthened against the greenback in a coordinated shift away from dollar positions. Currency strategists cite policy uncertainty as the primary driver, with the Federal Reserve's leadership transition scheduled for June 2026 prompting institutional hedging across portfolios worldwide.

Emerging market currencies faced divergent pressures. The Turkish Lira weakened as traders unwound carry trades that had exploited interest rate gaps between high-yielding developing economies and low-yielding Western currencies. The dollar's decline reduced returns on these positions, accelerating exits from leveraged forex strategies.

Trade-weighted indices confirmed broad dollar weakness against both major and emerging currency baskets. The decline represents the steepest fall since the Fed's 2022 tightening cycle ended and rate normalization began.

Geopolitical factors compound forex volatility. Progress in Iran-US nuclear negotiations adds variables to currency pricing models, particularly for petrodollar flows and Middle Eastern currency pegs tied to the dollar. Traders increased hedging as diplomatic developments accelerated.

Simon Phillips, Managing Director at No1 Currency, noted the British Pound faces pressure from UK fiscal concerns despite its 7% dollar gain, reflecting cross-currency dynamics as sterling benefits from dollar weakness while managing domestic headwinds.

Monetary policy divergence creates trading opportunities across regions. The Fed's uncertain trajectory contrasts with European Central Bank signals, pushing EUR/USD volatility to 2022 levels. Options markets priced elevated implied volatility through mid-2026, reflecting uncertainty around the Fed transition.

Forex volumes surged on major platforms as institutions repositioned globally. Multinational corporations increased currency hedge ratios to manage translation risks. Asset managers adjusted overlays to capture value between strengthening European currencies and weakening dollar positions.

Multiple data points supporting this realignment suggest sustained dollar weakness through the Fed transition period, with implications for global trade flows and cross-border investment strategies.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com